Telomir closes TELI merger, secures $5M funding, and receives FDA clearance for cancer trial

Filed May 14, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 14, 2025 · ~2 min read

Key Changes

• high

  FDA cleared IND application for Telomir-Zn trial in advanced triple-negative breast cancer, marking transition to clinical-stage development and triggering $2M milestone payment from Bayshore Trust.

  MD&A: FDA IND clearance verify on EDGAR →
• high

  TELI merger closed April 2026 with $1M immediate cash and $4M milestone-based funding commitment; company issued 34.4M shares to former TELI stockholders and consolidated worldwide rights to Telomir-1.

  MD&A: TELI merger verify on EDGAR →
• high

  Cash position improved 14x to $5.6M (vs $0.4M prior year) and runway extended to Q1 2027; going-concern doubt language removed following $6.5M ATM proceeds, $3M Bayshore financing, and $1M Starwood investment.

  MD&A: Liquidity verify on EDGAR →